The AAMC submitted comments on Jan. 27 in response to the Health Resources and Services Administration’s (HRSA’s) proposed rule addressing the 340B Administrative Dispute Resolution (ADR) process. The letter noted the association’s support of the ADR process as a way for covered entities to resolve certain disputes with drug manufacturers.
The comments stated that the AAMC supports an ADR process that is accessible to all covered entities and ADR disputes that are resolved in a timely manner. The association also noted its support of the inclusion of individuals with specific knowledge of the 340B Drug Pricing Program on the 340B ADR Panel. The letter asked HRSA to clarify that claims can be brought to the ADR process in response to drug manufacturers’ refusal to provide 340B pricing to certain covered entities and their community and specialty pharmacies or when manufacturers impose restrictions not required by the statute to receive 340B pricing.